Healthy
Conditions
Brief summary
The goal of this clinical trial is to understand the efficacy of Medicsen's Smartpatch to deliver drugs through the skin in healthy volunteers. The main questions it aims to answer are: * Is the administration with Medicsen Smartpatch safe for the patient? * Can Medicsen's Smartpatch be used to effectively administer drugs to patients? Researchers will compare administration with Medicsen's Smartpatch with the subcutaneous administration of the drug to see if the efficacy and safety are comparable Participants will be asked to fill a tolerability survey after receiving each of the two interventions: Subcutaneous administration and Medicse's Smartpatch. Blood samples will be taken at different timepoints to asses for efficacy of each treatment.
Detailed description
The clinical investigation will be conducted in two stages: Stage 1: A first-in-human pilot study to evaluate the safety, tolerability, and exploratory performance of the Medicsen Smartpatch for drug delivery in healthy volunteers: a single-center, open-label study. Stage 2: A confirmatory study to evaluate the performance of the Medicsen Smartpatch by comparing sonophoresis with subcutaneous drug delivery: a randomized, single-dose, open-label, two-way crossover study in healthy volunteers. Study subjects will be monitored for device-attributable adverse effects during the scheduled examinations and at any examinations resulting from study subjects' self-reported concerns. A licensed physician will review any unanticipated adverse events associated with the protocol.
Interventions
DEVICEMedicsen Smartpatch
This intervention consists of administering the drug using the Medicsen Smartpatch, a non-invasive, needle-free drug delivery device that utilizes sonophoresis technology to enhance absorption through the skin.
This intervention consists of administering the drug via standard subcutaneous injection using a pre-filled pen injector
Sponsors
Medicsensors S.L
SmartBIO Analytics
Hospital Universitario Ramon y Cajal
Avania
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects must provide signed informed consent prior to participation in any study related procedures * Healthy Caucasian volunteers, any sex, aged between 18 to 55 years * Body Mass Index (BMI) between 18.5 and 30.0 kg/m2 * Ability and agreement to comply with the study requirements * Medical history and physical examination within normal limits. * No clinically relevant abnormalities in hematology, biochemistry, virology, or urine tests. * Participants who engage in sexual activity which could result in pregnancy for themselves or their partner(s) must agree to use highly effective methods of contraception during the clinical investigation.
Exclusion criteria
* Case history of hypersensitivity to medicinal products or any other allergic process that could interfere with study according to the investigator's judgement. * Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, dermatology, gastrointestinal distress, hypertension, or infectious acute processes that could interfere with study according to the investigator's judgement. * Previous chronic processes or with rebound characteristics that could interfere with study according to the investigator's judgement. * Administration of topic or systemic medication including medicinal plants within 14 days before the intervention. * Presence of skin disorders or lesions at the intended application site (e.g., eczema, psoriasis, infections, open wounds), which may interfere with drug absorption or increase risk of adverse effects. * Implanted electronic medical devices, such as pacemakers or neurostimulators, due to potential interference with ultrasonic energy. * Pregnant or breastfeeding women, due to lack of safety data for either the drug or the ultrasound application in this population. * Severe cognitive or motor impairment, where safe operation of the patch cannot be ensured, unless under continuous caregiver supervision.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stage 1 - Device-related adverse events (adverse device effects; ADEs) | Periprocedural | Primary Outcome Measure of Stage 1. Incidence and severity of ADEs is assesed, with special focus on those occurred at the site of administration and those leading to treatment interruption. |
| Stage 1 - Assessment of local tolerability through questionnaires and visual examination | Periprocedural | Primary Outcome Measure of Stage 1. Subject-reported sensations (pain/burning, itching/stinging, discomfort) during and after administration are assesed through questionnaires. Dermatologist-evaluated skin signs (erythema, edema, vesicles, crusts/exudate, scaling/lichenification, hematomas/bleeding, tenderness) are assesed through visual examination. |
| Stage 2 - Area under the curve (AUC0-∞ and AUC0-t) | Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose | Primary Outcome Measure of Stage 2 |
| Stage 2 - Peak plasma concentration (Cmax) | Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose | Primary Outcome Measure of Stage 2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stage 1 - Peak plasma concentration (Cmax) | Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose | Secondary Outcome Measure of Stage 1. |
| Stage 1 -Area under the curve (AUC0-∞ and AUC0-t) | Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose | Secondary Outcome Measure of Stage 1. |
| Stage 1 - Tmax and t1/2 | Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose | Secondary Outcome Measure of Stage 1. |
| Stage 1 - Time at which the device notifies that the full dose has been delivered. | Periprocedural | Secondary Outcome Measure of Stage 1. |
| Stage 2 - Tmax and t1/2 | Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose | Secondary Outcome Measure of Stage 2. |
| Stage 2 - Incidence and severity of ADEs | Periprocedural | Secondary Outcome Measure of Stage 2. |
| Stage 2 - Number of participants with treatment-emergent clinically significant abnormalities in laboratory parameters (hematology and biochemistry) | Through study completion | Secondary Outcome Measure of Stage 2. Number of participants with laboratory values outside the normal reference range that are considered clinically significant compared to baseline. This includes hematology (hemoglobin, hematocrit, Red blood cell, MCV, MCH, MCHC, White blood cell with differential, and platelets) and biochemistry (urea, creatinine, glucose, AST (SGOT), ALT (SGPT), GGT, ALP, and total bilirubin). Unit of measure: Participants |
| Stage 2 - Number of participants with treatment-emergent clinically significant abnormalities in vital signs. | Through study completion | Secondary Outcome Measure of Stage 2. Number of participants with vital sign values outside the normal reference range that are considered clinically significant compared to baseline. This includes Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Heart Rate (HR), Respiratory Rate (RR), and Temperature (T) measured before and after the procedure. Unit of measure: Participants |
| Stage 2 - Number of participants with changes in electrocardiogram from baseline | Through study completion | Secondary Outcome Measure of Stage 2. A standard 12-lead ECG is performed with an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals before and after the procedure to determine changes from baseline values. |
| Stage 2 - Assessment of local tolerability through questionnaires and visual examination | Periprocedural | Secondary Outcome Measure of Stage 2. Subject-reported sensations (pain/burning, itching/stinging, discomfort) during and after administration of both interventions are assesed through questionnaires. Dermatologist- evaluated skin signs (erythema, edema, vesicles, crusts/exudate, scaling/lichenification, hematomas/bleeding, tenderness) after Medicsen Smartpatch intervention are assesed through visual examination. |
| Stage 2 - Time at which the device notifies that the full dose has been delivered. | Periprocedural | Secondary Outcome Measure of Stage 2 |
| Stage 2 - Usability endpoints (for healthcare professionals) | Immediately after the intervention | Secondary Outcome Measure of Stage 2. Rate of first-attempt success, time to complete setup, clarity of instructions, and user-reported ease-of-use scores for healthcare professionals are assesed through the Healthcare Proffesionals' Usability Questionnaire, in which a score from 1 to 5 is given to each of the measurements, and where a higher score means a worse outcome. |
| Stage 2 - Usability endpoints (for patients) | Immediately after the intervention | Secondary Outcome Measure of Stage 2. Comfort and willingness to reuse the device are assesed through the Patient's Usability Questionnaire, in which a score from 1 to 5 is given to each of the measures, and where a higher score means a worse outcome. |
Countries
Spain
Outcome results
None listed